Anti-viral pill 89% effective for high-risk Covid patients: Pfizer
New York: Pfizer Inc. today announced final results from an analysis of all 2,246 adults enrolled in its Phase 2/3 EPIC-HR (Evaluation of Protease Inhibition for COVID-19 in High-Risk Patients) trial of its novel COVID-19 oral antiviral…